MedTrace Logo

Clinical Study of Allergic Rhinitis Therapy by Stem Cells

NCT05151133 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-03-28

No results posted yet for this study

Summary

The investigators is now carrying out a clinical study of Umbilical cord Mesenchymal Stem Cells (UCMSCs) in the treatment of Allergic rhinitis (AR). UCMSCs is known to its multilineage differentiation potential, strong proliferation ability, low immunogenicity, convenient material acquisition, and fewer restrictions on ethical and moral issues. The investigators hope to find a novel, minimally invasive, effective and simple treatment for the large number of patients with persistent moderate to severe AR.

Conditions

  • Allergic Rhinitis

Interventions

BIOLOGICAL

Low dose UCMSCs

Receive one course of treatment with a single injection : 0.5×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;

BIOLOGICAL

Moderate dose UCMSCs

Receive one course of treatment with a single injection : 1.0×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;

BIOLOGICAL

High dose UCMSCs

Receive one course of treatment with a single injection : 2.0×10\^6 cells/kg, with a total volume of 100 ml UCMSCs;

Sponsors & Collaborators

  • Yantai Yuhuangding Hospital

    lead OTHER

Principal Investigators

  • Xicheng Song, MD · Yantai Yuhuangding Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-13
Primary Completion
2024-12-15
Completion
2024-12-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05151133 on ClinicalTrials.gov